Ligand Snaps Up Pfenex For Half A Billion
Value Of Transaction Could Top $500m Depending On Regulatory Milestone
Ligand Pharmaceuticals has struck a deal to acquire Pfenex in a transaction valued at up to $516m.
You may also be interested in...
Samsung Bioepis’ indication that it will not launch its FDA-approved ranibizumab biosimilar, Byooviz, before June 2022 has changed what we know about the competitive landscape for Lucentis in the US.
After launching in the US last year, the teriparatide product developed by Pfenex and Alvogen has been introduced in Europa, via commercialization partner Theramex, beginning with Germany.
Mergers and acquisitions have long been a tool for value creation in the generics and biosimilars space. Even with the entire life sciences sector overwhelmed by the novel coronavirus pandemic, deals big and small continued in 2020.